Rapport Therapeutics Inc <RAPP.OQ> expected to post a loss of 83 cents a share - Earnings Preview
Rapport Therapeutics Inc RAPP.OQ RAPP.O is expected to show no change in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Rapport Therapeutics Inc is for a loss of 83 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Rapport Therapeutics Inc is $35.00, about 59.6% above its last closing price of $14.15
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.77 | -0.76 | -0.68 | Beat | 10.5 |
Dec. 31 2025 | -0.63 | -0.62 | -0.57 | Beat | 8.8 |
Sep. 30 2024 | -0.58 | -0.58 | -0.50 | Beat | 13.2 |
Jun. 30 2024 | -0.68 | -0.68 | -1.70 | Missed | -151.7 |
| |||||
|
This summary was machine generated August 4 at 13:21 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
